



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re th	he Applic	cation of:)	Group Art Unit:
	BAR-O	R)	Examiner:
Serial 1	No.: 10/7	23,247)))	INFORMATION DISCLOSURE STATEMENT
Filed: 1	Novembe	r 25, 2003)	255550475 05 MANUNO
Atty. F	ile No.: 4	172-82)	CERTIFICATE OF MAILING I HEREBY CERTIFY THAT THIS CORRESPONDENCE I
For:	COND	TMENT OF DISEASES AND ITIONS MEDIATED BY ASED PHOSPHORYLATION")))	BEING DEPOSITED WITH THE UNITED STATES POSTA SERVICE AS FIRST CLASS MAIL IN AN ENVELOP ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.C BOX 1450, ALEXANDRIA, VA 22313 ON THIS 27 DAY OF
Comm P.O. B	issioner f ox 1450	endments For Patents 22313-1450		SHERIDAN ROSS P.C. BY: Chasty Rev. Chasity C. Rossum
Sir:	•			
	The ref	erences cited on attached Form PT	O-1449	are being called to the attention of the Examiner.
	\boxtimes	Copies of the cited foreign pater	nts and/c	or non-patent references are enclosed herewith.
		Copies of the cited U.S. patents a	ınd/or U	.S. patent application publications are not enclosed
in acco	rdance w	vith 69 F.R. 56482.		
		Copies of the cited references are	not enc	closed, in accordance with 37 C.F.R. 1.98(d),
	e the refe			and Trademark Office in prior application Serial No ed upon for an earlier filing date under 35 U.S.C. §
120.	_		.1	CAL - Course law representation and annual con-
	□			nence of the foreign-language references are
• • • • • • • • • • • • • • • • • • • •				ts and in the figures, although applicants do not
necess	Ė	ch for the accuracy of the translation		llowing co-pending application(s) for which priority
is not t	being ciai	med, copies have been or are bein		
				(Atty. Dckt. No)
	└ 11			llowing co-pending application(s), to which the
			isi ine ci	aims for such pending application are provided or
nave b	een provi		filed	(Atty. Dckt. No)
		Serial No.	11160	(Auy. Dekt. No.

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

X	37 CFR 1.97(b): No	o fee is believed due in connection with this submission, because the information disclosure statement
	submitted herewith	is satisfies one of the following conditions ("X" indicates satisfaction):
		Within three months of the filing date of a national application other than a continued prosecution
		application under 37 CFR 1.53(d), or
		Within three months of the date of entry into the national stage of an
		international application as set forth in 37 CFR 1.491 or
	⊠	Before the mailing date of a first Office Action on the merits, or
		Before the mailing of a first Office action after the filing of a Request for
		Continued Examination (RCE) under 37 CFR 1.114.
	Although no fee is b	believed due, if any fee is deemed due in connection with this submission, please charge such fee to
	Deposit Account 19	-1970.
	37 CFR 1.97(c): Th	e information disclosure statement transmitted herewith is being filed after all the above conditions (37
	CFR 1.97(b)), but l	pefore the mailing date of one of the following conditions:
		(1) a final action under 37 C.F.R. 1.113 or
		(2) a notice of allowance under 37 C.F.R. 1.311, or
		(3) an action that otherwise closes prosecution in the application.
	This Information D	isclosure Statement is accompanied by:
		Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is
	deemed due in conr	ection with this submission, please charge such fee to Deposit Account 19-1970.
		OR
		check in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an
	information disclos	ure statement. Please credit any overpayment or charge any underpayment to Deposit Account No. 19-
	1970.	
	37 CFR 1.97(d): Ti	nis Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c).
	☐ This	s information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e)
		AND
	☐ Ap	plicants hereby requests consideration of the reference(s) disclosed herein. Enclosed is the fee in the
	amount of \$180.00	under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to Deposit
		70. Please credit any overpayment or charge any underpayment to Deposit Account No. 19-1970.
		fee should not be taken as an indication that applicant(s) cannot execute a certification.

Certification (37 C.F.R. 1.97(e)) (Applicable only if checked) The undersigned certifies that: Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1). A copy of the communication from the foreign patent office is enclosed. OR No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).

Respectfully submitted,

SHERIDAN ROSS, P.C.

Mary B. Smith

Registration No. 43,512 1560 Broadway, Suite 1200

B Smith

Denver, CO 80202-5141 TELEPHONE: 303-863-9700

FAX: 303-863-0223

Date: 5/27/20

J:\4172\-82\IDS-002.wpd

	Comple	te if Known
Substitute for form 1449A/PTO	Application Number	10/723,247
THE INFORMATION DISCLOSURE	Filing Date	November 25, 2003
WIND STATEMENT BY APPLICANT	First Named Inventor	BAR-OR
W 31 2005 ENEMENT BI AFFEIGART	Art Unit	1632
(MA S	Examiner Name	Not Yet Assigned
Sheet 1 of 1	Attorney Docket Number	4172-82

			U.S. PATENT DOC	CUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

			FOREI	GN PATENT DO	CUMENTS		
Examiner Initials*	Cite No. ¹		eign Patent Document Number*; Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T€
		-					$oldsymbol{oldsymbol{\perp}}$
· · · · · · · · · · · · · · · · · · ·							丄
		·					丄

		OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)
Examiner Initials*	Cite No.1	
	1	Takeishi et al.; "In Vivo Phosphorylation of Cardiac Troponin I by Protein Kinase Cβ2 Decreases Cardiomyocyte Calcium Responseiveness and Contractility in Transgenic Mouse Hearts"; <i>J. Clin. Invest.</i> ; July 1998; 102(1):72-78
.,		

Date Considered	

^{*}EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

J:\4172\-82\1449-002.wpd